Aktiesnakken — Juli 2012
-
forventet
-
jeg holder til på MI's pottegruppe
-
ja der er kæmpe forskel.
-
men havde Sanofi købt Byetta og Bydereon skulle deres sælgere jo sælge både de 2 og Lyxumia
-
Nu skal de fokusere 100% på lyxumia som deres eneste GLP-1
-
der er for mig at se kæmpe forskel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind